On Track Innovations (OTIV) Misses Q1 EPS by 1c, Miss on Revenues
Get Alerts OTIV Hot Sheet
Price: $0.17 --0%
Financial Fact:
Financial expenses, net: -30K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Financial expenses, net: -30K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
On Track Innovations (NASDAQ: OTIV) reported Q1 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.08 million.
Q1 2017 Operational Highlights
- Received purchase orders for thousands of cashless payment solutions for the growing fast food self-serve kiosk market, to be delivered during 2017.
- Received purchase order for first installment of cashless payment systems sale into Japanese market
- Enhanced sales organization depth and capabilities with the appointment of Larry Susman as Vice President of Sales
Q1 2017 Financial Details
- Total quarterly revenue decreased to $4.0 million, a 28% decrease from $5.6 million in the prior quarter and a 12% decrease from $4.6 million in the same year-ago period.
- Gross profit as a percentage of revenues increased to 55%, a 12% increase over 43% in the prior quarter and an increase of 4% over 51% in the same year-ago period.
- Operating expenses decreased to $2.9 million, a 13% decrease from $3.4 million in the prior quarter and a 3% decrease from $3.0 million in the same year-ago period.
- Net cash used in continuing operating activities decreased 43% to $0.7 million compared to $1.2 million in the same year-ago period.
- Cash, cash equivalents and short-term investments at March 31, 2017 totaled $10.8 million, a decrease of 6% from December 31, 2016 and an increase of 13% from the same year-ago period.
For earnings history and earnings-related data on On Track Innovations (OTIV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share